The Emerging Role of GABAergic Mechanisms in Mood Disorders

Psychiatric Times September 2005 Vol. XXII Issue 10

Sponsored by CME LLC for 2.5 Category 1 credits.
Original release date 9/05. Approved for CME credit through 8/31/06.

Educational Objectives:

• The basic physiology of GABA neurotransmission.
• The importance of GABA in animal models of depression.
• The diverse range of medications that have GABAergic effects and efficacy in mood disorders.
• Targets of future drug development based on commonalities of drug effects.

Who will benefit from reading this article?

Psychiatrists, primary care physicians, neurologists, nurse practitioners, psychiatric nurses and other mental health care professionals. Continuing medical education credit is available for most specialties. To determine if this article meets the CE requirements for your specialty, please contact your state licensing board.

Dr. Wang is acting assistant professor of psychiatry and behavioral sciences at the Stanford University School of Medicine Bipolar Disorders Clinic. Dr. Wang has received grant/research support and lecture honoraria from Abbott Laboratories, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer Inc. He has also received grant/research support from Bristol-Myers Squibb Company, Elan Pharmaceuticals, Janssen Pharmaceutica, Shire Laboratories and Wyeth.

Dr. Ketter is professor of psychiatry and behavioral sciences and chief of the Bipolar Disorders Clinic at the Stanford University School of Medicine. Dr. Ketter has received grants and research support, honoraria, served as a consultant and member of the speakers' bureau for Abbott Laboratories; AstraZeneca Pharmaceuticals, L.P.; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceutica Products, L.P.; and Wyeth. He also receives grants and research support from and serves as a consultant for Elan Pharmaceuticals and Shire US Inc. He serves as a consultant for and receives honoraria from Novartis Pharmaceuticals. He also serves as a consultant for Cephalon, Inc.